Finalist
A Global Database of Lung Cancer Screening
In 2022, the Lung Cancer Policy Network was funded by AstraZeneca, Guardant Health, Johnson & Johnson and Medtronic
Summary of work
Lung cancer is the world’s leading cause of cancer-related deaths. Targeted screening via low-dose computed tomography (LDCT) is the best way to detect and treat lung cancer early.
Forty years’ worth of evidence shows that LDCT lung cancer screening improves outcomes. However, many countries have not started planning to introduce lung cancer screening, and information on existing initiatives is challenging to find.
The Lung Cancer Policy Network – a global membership group of 50 experts supported with funding from AstraZeneca, Guardant Health, Johnson & Johnson and Medtronic, and run by The Health Policy Partnership – set out to create the first robust, global database on LDCT screening. Through our rigorous desk research, we developed a detailed database with information on 133 initiatives across 38 countries and 70 variables. Presenting this information via an interactive map and summary report, we contextualised data and presented learnings.
By providing advocates and policymakers with this peer-reviewed data and robust analysis, we can elevate the case for LDCT screening and focus on improving design and delivery of future initiatives. Our data has influenced high-level policy discussions, and established a respected platform to facilitate knowledge exchange and shape new data-driven policies to improve outcomes for people with lung cancer.
Judges’ comments
The ‘A Global Database of Lung Cancer Screening’ was a strong entry, with decent and considered communications perspectives. It had a very effective use of data to provide much-needed information for policymakers to drive change.
